Delving into the Latest Updates on Chengdu Guowei Biopharmaceutical Co. Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

siRNA

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
siRNA	1

Top 5 Target	Count

κ opioid receptor(Kappa opioid receptor)	1
AGT(Angiotensinogen)	1

本试验旨在研究单次空腹和餐后口服四川国为制药有限公司研制、生产的艾普拉唑肠溶片（5 mg）的药代动力学特征；以丽珠集团丽珠制药厂持证、生产的艾普拉唑肠溶片（壹丽安®，5 mg）为参比制剂，比较两制剂中药动学参数 Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

This study aimed to investigate the pharmacokinetic characteristics of ilaprazole enteric-coated tablets (5 mg) developed and produced by Sichuan Guowei Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal. Using ilaprazole enteric-coated tablets (Yili'an®, 5 mg) licensed and produced by Livzon Pharmaceutical Factory under the Livzon Group as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate their bioequivalence in humans.

Start Date22 Jun 2025

Sponsor / Collaborator

Sichuan Guowei Pharmaceutical Co., Ltd.

CTR20251035

/ RecruitingPhase 1

GW906注射液在中国健康受试者和轻度高血压受试者中的安全性、耐受性、药代动力学和药效学特征的I期临床研究

[Translation] A Phase I clinical study of the safety, tolerability, pharmacokinetics and pharmacodynamics of GW906 injection in Chinese healthy subjects and subjects with mild hypertension

评价GW906注射液在健康受试者和轻度高血压受试者中单次皮下注射的安全性和耐受性。

[Translation]

To evaluate the safety and tolerability of a single subcutaneous injection of GW906 injection in healthy subjects and subjects with mild hypertension.

Start Date27 Mar 2025

Sponsor / Collaborator

Chengdu Guowei Biopharmaceutical Co. Ltd.

[+1]

CTR20250875

/ RecruitingNot Applicable

艾普拉唑肠溶片在健康人体的单中心、随机、开放性生物等效性试验

[Translation] A single-center, randomized, open-label bioequivalence study of ilaprazole enteric-coated tablets in healthy volunteers

以四川国为制药有限公司生产的艾普拉唑肠溶片为受试制剂，以丽珠集团丽珠制药厂生产的艾普拉唑肠溶片为参比制剂，考察两制剂的生物等效性。

[Translation]

The bioequivalence of the two preparations was investigated using ilaprazole enteric-coated tablets produced by Sichuan Guowei Pharmaceutical Co., Ltd. as the test preparation and ilaprazole enteric-coated tablets produced by Livzon Pharmaceutical Factory of Livzon Group as the reference preparation.

Start Date07 Feb 2025

Sponsor / Collaborator

Sichuan Guowei Pharmaceutical Co., Ltd.

100 Clinical Results associated with Chengdu Guowei Biopharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Chengdu Guowei Biopharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Chengdu Guowei Biopharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Chengdu Guowei Biopharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 16 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

1

2

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

GW906 ( AGT )	Essential Hypertension More	Phase 1
Difelikefalin acetate ( κ opioid receptor )	Chronic Kidney Disease-Associated Pruritus More	Phase 1
GW901	Hypertriglyceridemia More	IND Approval